Phoenix Molecular Designs
Vancouver
About Phoenix Molecular Designs
Phoenix Molecular Designs is developing precise cancer therapeutics with a platform technology focused on developing first- and best-in-class kinase inhibitors designed to uniquely target p90 ribosomal S6 kinase (RSK). Their world-renowned leadership team boasts over 100 years of oncology experience from notable affiliations such as Genentech, Pfizer and Eli Lily. The company completed a Phase 1 first-in-human clinical trial with lead asset, PMD-026 treating women with metastatic breast cancer. A Phase 1b mono-therapy trial in triple negative breast cancer (TNBC) in 9 leading medical centers across the United States has also been completed with results providing further evidence of the benefit of inhibiting RSK in breast cancer. A phase 2a trial in HR+/HER2- metastatic breast cancer is currently underway at a number of leading academic research hospitals. RSK inhibition has also been proven to provide benefits in multiple hematologic cancers in the hematologic malignancies space as well.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $12.3M
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2020)
- Website: phoenixmd.ca
- Phone: +1 604 674 1796
Industries & Categories
Biotechnology, Health Care, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/phoenix-molecular-designs-55462 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.